Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics

Core Insights - Bausch Health reported revenue of $2.56 billion for Q4 2024, a 6.3$1.21, up from $1.15 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of$2.51 billion, resulting in a surprise of +1.89%, while EPS also surpassed expectations by +8.04% [1] Revenue Breakdown - Total Bausch + Lomb revenues reached $1.28 billion, exceeding the average estimate of$1.23 billion, marking a year-over-year increase of +9.1% [4] - Revenues from Diversified Products were $228 million, below the average estimate of$252.98 million, reflecting a year-over-year decline of -12% [4] - Vision Care revenues amounted to $723 million, surpassing the estimated$698.94 million, with a year-over-year increase of +9.2% [4] - Ophthalmic Pharmaceuticals generated $326 million, slightly above the average estimate of$317.99 million [4] - International revenues were $279 million, falling short of the estimated$294.30 million, representing a year-over-year decrease of -3.8% [4] - Solta Medical revenues reached $138 million, exceeding the average estimate of$115.36 million, with a significant year-over-year increase of +34% [4] - Total revenues excluding Bausch + Lomb were $1.28 billion, slightly above the estimated$1.26 billion, reflecting a +3.6% year-over-year change [4] - Salix revenues were $634 million, surpassing the average estimate of$598.47 million, with a year-over-year increase of +8.8% [4] - Revenues from Diversified Products-Generics were $9 million, significantly below the estimate of$17.13 million, showing a drastic decline of -67.9% year-over-year [4] - Revenues from Diversified Products-Dentistry were $24 million, slightly above the estimate of$23.49 million, with a year-over-year decrease of -17.2% [4] - Other revenues reached $31 million, exceeding the estimate of$23.37 million, marking a year-over-year increase of +19.2% [4] - Revenues from Diversified Products-Neuro were $142 million, below the average estimate of$159.79 million, with a year-over-year change of +0.7% [4] Stock Performance - Bausch shares have declined by -14.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of +2.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]